Zealand Pharma A/S

DK

Health Care

581.5 ₽

Current price

Sell
581.5 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    343 / 1361

  • Position in country

    127 / 253

  • Return on Assets, %

    -41.6

    -40.3

  • Net income margin, %

    -1139.5

    -180

  • EBITDA margin, %

    -1043.4

    -168.2

  • Debt to Equity, %

    7.4

    3.2

  • Intangible assets and goodwill, %

    0.6

    0.2

  • Revenue CAGR 3Y, %

    21.3

    12.5

  • Total Equity change 1Y, %

    100.7

    -9

  • Revenue Y, % chg

    238.8

    0

  • P/BV

    21.6

    1.8

  • P/S

    107.7

    10.3

  • EV/S

    103.3

    7.5

  • EV/EBITDA

    -38.8

    -1.6

  • Average Analyst recommendation

    Buy

    Buy

  • Average upside forecasts, %

    42

    131.1

  • Expected dividend per share

    0

    0

Get an analytical review of this company

Competitors

Ranks

  • Bavarian Nordic A/S

    00%

  • Vertex Pharmaceuticals Inc

    00%

  • CSL Ltd

    00%

  • Regeneron Pharmaceuticals Inc

    00%

  • Gilead Sciences Inc

    00%

  • Genmab A/S

    00%

  • Ascendis Pharma A/S

    00%

  • Zealand Pharma A/S

    00%

  • Amgen Inc

    00%

  • AbbVie Inc

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    Denmark

  • Sector

    Health Care

  • Industry group

    Pharmaceuticals, Biotechnology & Life Sciences

  • Industry

    Biotechnology

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    5310.8

  • Ticker

    ZELA.CO

  • ISIN

    DK0060257814

  • IPO date

    2010-11-01

  • Availability on Russian exchanges

    No

  • Reporting for

    2024-02-27

  • Date fact. publication of reports

    2023-12-31

Company Description

Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area offers ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment. Furthermore, the Company collaborates with a number of partners, such as Sanofi, Helsinn, Boehringer Ingelheim, Abbvie and Eli Lilly.

A step towards better analytics

  • find the best promotions through the Screener
  • keep an eye on stock valuation
  • download detailed reports

and much more after free registration

Registration

More convenient from your phone? Download: